Ibrahim T, et al. - In this retrospective single-institution cohort study, researchers tested the effectiveness and tolerability of immunotherapy among elderly patients with melanoma via analyzing data of study participants aged 75 years and above who had been treated with nivolumab, pembrolizumab or ipilimumab for advanced or metastatic melanoma. The main finding of this study was that immunotherapy was effective and well tolerated in the elderly. Results of this study revealed that the PFS associated with pembrolizumab was greater than expected.